Bristol-Myers Squibb Company logo

Bristol-Myers Squibb Company (BMY)

Market Closed
18 Jul, 20:00
NYSE NYSE
$
47. 36
-0.7
-1.46%
$
95.36B Market Cap
- P/E Ratio
2.4% Div Yield
10,713,300 Volume
- Eps
$ 48.06
Previous Close
Day Range
47.26 48.24
Year Range
41.61 63.33
Want to track BMY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 11 days
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 day ago
Will Increased Expenses Affect Bristol Myers' Performance?

Will Increased Expenses Affect Bristol Myers' Performance?

BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.

Zacks | 3 days ago
Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends

Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends

The Dividend Harvesting Portfolio hit new all-time highs in value, profitability, and forward income, with a 29.58% return on invested capital. Consistent weekly investing, diversification, and a focus on income-producing assets have driven strong performance, even through volatile markets and macroeconomic headwinds. I see significant opportunities ahead, especially for big tech, REITs, and energy stocks, as the Fed's delayed rate cuts create a favorable environment.

Seekingalpha | 1 week ago
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company

Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company

Bristol Myers Squibb is undervalued despite the looming patent cliff, as its robust pipeline and strong cash flow position it for future growth. The impact of Eliquis' patent expiry is overstated, since only half its revenue affects BMY's bottom line due to the Pfizer partnership. Earnings have been depressed by past acquisition amortizations, but these charges will drop sharply, revealing stronger profitability.

Seekingalpha | 1 week ago
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $47.66, denoting a +1.32% move from the preceding trading day.

Zacks | 1 week ago
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?

Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?

BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.

Zacks | 1 week ago
2 Wonderful Dividends At Bargain Basement Prices

2 Wonderful Dividends At Bargain Basement Prices

Uncertainty creates value opportunities. In this article, I highlight two value stocks trading far below their historical valuations. Both offer dividend yields that are well above historical average and strong growth potential. Both stocks exemplify how investors can secure decent yields and future upside by buying quality companies when market sentiment is overly pessimistic.

Seekingalpha | 1 week ago
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 week ago
Boomers Are Grabbing These Big Beautiful Blue-Chip Dividend Giants For Decades of Passive Income

Boomers Are Grabbing These Big Beautiful Blue-Chip Dividend Giants For Decades of Passive Income

Blue-chip dividend stocks are shares of large, well-established, financially stable companies with a consistent and reliable performance history.

247wallst | 1 week ago
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?

Will The Decline in Legacy Drugs Pull Down BMY's Top Line?

Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.

Zacks | 2 weeks ago
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note

Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note

Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.

Zacks | 2 weeks ago
Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset

Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset

Initiate Bristol-Myers Squibb (BMY) with Buy and $57 PT, driven by high-momentum launches, robust pipeline, and underappreciated growth portfolio outperformance. BMY's $13bn+ annual FCF, strong balance sheet, and disciplined capital returns provide downside protection and support ongoing R&D and M&A activity. Our above-consensus FY25/26 revenue forecasts reflect accelerating adoption of Opdivo, Cobenfi, and Camzyos, offsetting legacy product erosion and regulatory headwinds.

Seekingalpha | 2 weeks ago
Loading...
Load More